Search for: "Commercial Factors of Atlanta, Inc."
Results 21 - 36
of 36
Sorted by Relevance
|
Sort by Date
2 Aug 2008, 12:54 am
: (Holman’s Biotech IP Blog), Daiichi’s open offer for 20% in Ranbaxy awaits Sebi nod: (GenericsWeb), Australia/India: Strides shows thumbs up for Indian generic industry acquiring controlling interest in Ascent: (Spicy IP), Europe: Significant date ahead for EU Paediatric Regulation: (SPC Blog), India: Grave diggers, ‘immoral’ patent and the National Biotech Regulatory Authority: (Spicy IP), UK: Monster trade mark infringement case: court reveals its thinking… [read post]
31 Jul 2008, 1:38 am
The duration of the illness is from 1 to 10 (or more) days, depending on host-resistance, the amount of toxin ingested, and other factors. [read post]
23 Sep 2009, 12:45 am
The duration of the illness is from 1 to 10 (or more) days, depending on host-resistance, the amount of toxin ingested, and other factors. [read post]
23 Nov 2010, 11:43 am
The duration of the illness is from 1 to 10 (or more) days, depending on host-resistance, the amount of toxin ingested, and other factors. [read post]
5 Aug 2014, 5:22 pm
The duration of the illness is from 1 to 10 (or more) days, depending on host-resistance, the amount of toxin ingested, and other factors. [read post]
6 Aug 2014, 6:36 am
The duration of the illness is from 1 to 10 (or more) days, depending on host-resistance, the amount of toxin ingested, and other factors. [read post]
3 May 2016, 12:09 am
The duration of the illness is from 1 to 10 (or more) days, depending on host-resistance, the amount of toxin ingested, and other factors. [read post]
13 Nov 2009, 10:24 am
Click here for entire article Atlanta Airport Project Gets Stimulus Funds. --- LexisNexis, October 30, 2009. [read post]
27 Aug 2020, 8:07 am
Plaid Inc. [read post]
18 Apr 2008, 2:00 am
Lélos Kai Sia EE (and Others) v GlaxoSmithKline AEVE: (IPKat), US: Bio commends Sen Specter for patent reform stance: (Patent Docs), US: USPTO rules on two of four neural stem cell patents in dispute between StemCells Inc and Neuralstem Inc; parties disagree on how extensively claims amended: (IP Law360), (IPBiz), US: Insmed continues fight for generic biologic approval: (GenericsWeb), Pharma & Biotech - Products Cipralex (Escitalopram)… [read post]
9 Aug 2008, 1:50 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: The end of William Patry’s blog: (Patry Copyright Blog), (Excess Copyright), (Patently-O), (Chicago IP Litigation Blog), (Michael Geist), (The Fire of Genius), (Techdirt), (Patry Copyright Blog), Kitchin J clarifies scope of biotech patents, in particular gene sequence patents: Eli Lilly & Co v Human Genome Sciences: (Managing… [read post]
18 Jul 2008, 8:34 am
: (Patent Circle), Tanzania to conduct study on impact of counterfeit medicines: (Afro-IP), US: New rules on generic biological medicines under US Congressional debate: (Intellectual Property Watch), Pharma & Biotech - Products Acular (Ketorolac) – US: CAFC rules against Apotex reverse doctrine of equivalents: Roche Palo Alto & Allergan, Inc v Apotex: (Patent Circle), Carbatrol (Carbamazapine) – US: Federal judge allows Corepharma to seek DJ that its… [read post]
20 Jun 2008, 8:07 am
: (IP finance), Technical assistance a key point of discussion at TRIPS Council: (Intellectual Property Watch), WIPO turmoil as new DG’s future comes under threat: (IAM), WIPO to host inter-regional forum to explore strategies to enhance development and service-orientation of IP offices: (WIPO), Controversy over lack of transparency and overreaching enforcement provisions in ACTA: (Spicy IP), (Spicy IP) Global - Trade Marks / Domain Names / Brands World anti-counterfeiting day:… [read post]
17 Sep 2011, 4:07 am
http://j.st/qD9 The Glenelk Ass'n, Inc. v. [read post]
24 Mar 2023, 4:00 am
Even as companies scramble to join the commercial boom prompted by the release of ChatGPT, they face a debate over the use, and potential abuse, of artificial intelligence. [read post]
18 Oct 2023, 1:52 pm
[Serial-blogging my recent article in the Journal of Free Speech Law] Previously, I blogged the abstract, introduction, Part I, and Part II of my new article, Taxing Nudity: Discriminatory Taxes, Secondary Effects, and Tiers of Scrutiny, which has just been published in the Journal of Free Speech Law. [read post]
